Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
about
Advanced MRI in the management of adult gliomas.Biology, genetics and imaging of glial cell tumoursGenetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markersCerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours.Relative survival of patients with supratentorial low-grade gliomasGenetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasmsMolecular diagnostic testing in malignant gliomas: a practical update on predictive markers.An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.What is the clinical value of cancer stem cell markers in gliomas?Biomarkers classification and therapeutic decision-making for malignant gliomas.Outcomes in Reoperated Low-Grade Gliomas.Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy.Tumor prognostic factors and the challenge of developing predictive factors.Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?Gene expression in oligodendroglial tumors.Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.Genomic aberrations in diffuse low-grade gliomas.
P2860
Q31139548-CAEB0C29-F86E-4A16-A75F-6C9A96E8865BQ34203979-A3107A47-5BF9-4F38-8F76-63440FB327FEQ34796547-C580CB95-46A4-4B8B-AA41-F311DAFA7ADDQ34815207-9B03A996-9B5B-4573-8ED6-827336C8ED06Q35070122-472F67B6-DF8A-4F5A-875B-10F20E89AF18Q36127462-98A83597-B05B-4042-930E-4F6FE3C6C45CQ36612016-35CBEE6A-AE46-44A4-8A92-5FE00F0DD0ADQ37037132-911A84D0-6B21-4F55-A770-0357A8D23190Q37858468-B54ECA65-8F7C-4DA0-8D0C-1009EE64718EQ38081776-0C52241F-0D24-473A-B962-9F7F95C3BF9EQ39556985-6A772F1D-B752-4E7D-91EE-702F61B2EB74Q41104618-E3DB92E1-2B72-41C1-81E3-383A39A4FDDFQ44453455-DADBD3EE-D4D8-47A5-9504-33EB0C602543Q48182114-7C458AC0-13F9-4FC2-B3E4-925449146A23Q48260561-DB45EB86-18CB-4B66-ACB8-D195DA19E599Q48261931-428C864F-96A1-4EDE-A145-EFF32743E22EQ54368368-D3713C92-1116-4BB8-B63A-6A52F50DB0BCQ54459761-0CD19911-2D6A-4DD0-BE1B-D5C0A69A8315Q55463309-F9E427EF-7FA6-4E6B-B065-EAB3121E8854
P2860
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
@ast
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
@en
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
@nl
type
label
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
@ast
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
@en
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
@nl
prefLabel
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
@ast
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
@en
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
@nl
P2093
P1433
P1476
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors
@en
P2093
du Plessis DG
P304
P356
10.1212/01.WNL.0000218270.12495.9A
P407
P577
2006-06-01T00:00:00Z